7Baggers

We provide you with 20 years of free, institutional-grade data for REPL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of REPL. Explore the full financial landscape of REPL stock.

Reported DateCIKTickerType
2024-02-081737953REPL10-QUrl
2023-11-071737953REPL10-QUrl
2023-08-031737953REPL10-QUrl
2023-05-181737953REPL10-KUrl
2023-02-091737953REPL10-QUrl
2022-11-031737953REPL10-QUrl
2022-08-041737953REPL10-QUrl
2022-05-191737953REPL10-KUrl
2022-02-031737953REPL10-QUrl
2021-11-041737953REPL10-QUrl
2021-08-061737953REPL10-QUrl
2021-05-201737953REPL10-KUrl
2021-02-041737953REPL10-QUrl
2020-11-051737953REPL10-QUrl
2020-08-071737953REPL10-QUrl
2020-06-031737953REPL10-KUrl
2020-02-131737953REPL10-QUrl
2019-11-121737953REPL10-QUrl
2019-08-141737953REPL10-QUrl
2019-06-281737953REPL10-KUrl
2019-02-141737953REPL10-QUrl
2018-11-141737953REPL10-QUrl
2018-08-301737953REPL10-QUrl
2018-06-221737953REPLS-1Url

Replimune Group, Inc
(NASDAQ:REPL) 

REPL stock logo

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a...

Founded: 2015
Full Time Employees: 122
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about REPL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.